Septerna raised $288 million in an IPO to support its drug development efforts.
02/14/25, 5:26 PM
Location
san franciscoMoney raised
$288 million
Septerna, a San Francisco area drugmaker, recently went public and raised $288 million through its IPO. The company, alongside other biotech leaders, discussed the challenges of transitioning from private to public markets at a recent panel event.
Company Info
Location
san francisco, california, united states
Additional Info
Septerna, Inc., is a biotechnology company creating broad new drug discovery opportunities across many disease areas for the abundant drug target class of G protein-coupled receptors (GPCRs). The company’s Native Complex™ Platform recapitulates GPCRs with their native structure, function, and dynamics outside of the cellular environment to enable new technologies for industrial-scale drug discovery for the entire GPCR target class for the first time. Septerna has an emerging pipeline of GPCR-targeted small molecule drug discovery programs, along with growth potential to reach many GPCRs that have been undruggable and unexploited to date. Septerna was launched in 2022 by scientific founders who have made groundbreaking GPCR discoveries and by founding investor Third Rock Ventures. For more information, please visit www.septerna.com. Please follow us on LinkedIn and @Septerna_Inc.